The Medical letter on drugs and therapeutics|2026|Unknown authors
PMID: 42068314
A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Cardiovascular outcome trials of the incretin-based medicines tirzepatide and semaglutide have shown benefits in populations with varying levels of cardiovascular risk. However, without direct head-to-head comparisons, treatment decisions rely on ind…
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes in addition to other conditions such as obesity. As their use expands, understanding potential ocular safety signals is important, particularly in p…
IMPORTANCE: Metabolic dysfunction-associated steatotic liver disease (MASLD) includes a range of liver conditions, progressing from isolated steatosis (characterized by fat accumulation in the liver without inflammation) to metabolic dysfunction-asso…
BACKGROUND: Psoriasis is associated with a significant comorbidity burden, especially cardiovascular and metabolic complications. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, used to treat obesity and diabetes, could pot…
AIMS: To evaluate the associations between semaglutide initiation and long-term skeletal outcomes in people with obesity, stratified by type 2 diabetes (T2D) status, using target trial emulation. MATERIALS AND METHODS: This retrospective cohort study…
BACKGROUND: Obesity is a chronic metabolic disease associated with substantial cardiometabolic risk and long-term morbidity. Although randomized controlled trials have demonstrated the efficacy of incretin-based therapies, real-world comparative data…
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity and insulin resistance, and sustained weight loss is associated with histological improvement. Whether different obesity-management modalities e…
AIMS: To evaluate glycemic control, weight management, and patient-reported outcomes (PROs) in adults with type 2 diabetes mellitus who transitioned to oral semaglutide (OS) after inadequate glycemic control on dipeptidyl peptidase-4 inhibitors (DPP-…
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease is common among individuals with type 2 diabetes mellitus and substantially increases the risk of liver cirrhosis and hepatocellular carcinoma. Effective therapies that improve meta…
BACKGROUND AND AIMS: Semaglutide, a glucagon-like peptide-1 receptor agonist, is effective in the treatment of fibrotic (F2-F3) metabolic dysfunction-associated steatohepatitis (MASH) and has recently received accelerated Food and Drug Administration…
BACKGROUND: Health Canada is proposing to use decisions by foreign regulators in approving new drugs to speed up their marketing. OBJECTIVES: To investigate the length of gaps in submissions to and approvals by Health Canada compared to the Food and…
BACKGROUND/AIMS: : Semaglutide is associated with gastroduodenal symptoms, such as nausea and vomiting. This pilot study used body surface gastric mapping (BSGM) to measure the effect of semaglutide on gastric function and associated symptoms. METHOD…
BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a progressive condition characterized by excess hepatic fat accumulation in the absence of significant hepatocellular injury. Its more severe form, metabolic dys…
Abdominal aortic aneurysm (AAA) is a vascular disease characterized by the progressive dilation of the aorta, culminating in rupture. At present, there are no pharmacological treatments to prevent AAA development or reduce rupture rate. A recent stud…
AIM: A retrospective observational cohort study, in the Netherlands, evaluated clinical outcomes with oral semaglutide. METHODS: Glucagon-like peptide-1 receptor agonists (GLP-1ra) naïve type 2 diabetes (T2D) patients who initiated oral semaglutide b…